Citations

Clear

16280 citation(s) found for "Yu, David".

Comparing the clinical utility of pharmacogenomic genotyping and next generation sequencing in a military health system adult medicine clinic
Saunders, David , Hellwig, Lydia D. , Pagani, Austin, Castro, Mauricio De , Poon, Lucas, Ehat, Nate, Heroy, Andrew , Libbus, Joya, Fox, Keiko , Kalra, Sachi, Black, John L. , Scherer, Steven E. , Moyer, Ann M. , Black, John Logan, Haigney, Mark C. , Kalra, Sachi, Arnold, Thomas B. , Turner, Clesson

Mayo Clinic

Pharmacogenomics | February 21, 2025 | Volume: 25 | Issue: 16-18 | Pages: 637-645

10.1080/14622416.2025.2466413 | PMID 39981562 Get It

Sex differences in effectiveness of CGRP receptor antagonism for treatment of acute and persistent headache-like pain in a mouse model of mild traumatic brain injury
Navratilova, Edita , Kopruszinski, Caroline Machado , Oyarzo, Janice, Barber, Kara R. , Schwedt, Todd J. , Porreca, Frank , Kopruszinski, Caroline , Schwedt, Todd J , Porreca, Frank , Navratilova, Edita , Anderson, Trent , Dodick, David W.

Mayo Clinic

Cephalalgia | February 21, 2025 | Volume: 45 | Issue: 2 | Pages: No page available

10.1177/03331024251321087 | PMID 39980371 Get It

Background Traumatic brain injury (TBI) commonly elicits acute (APTH) and/or persistent (PPTH) post-traumatic headache. Calcitonin gene related peptide (CGRP) has been implicated as a contributor to PTH pathophysiology. We explored the possibility of sexual dimorphism in the effects of CGRP receptor (CGRP-R) blockade in a preclinical model of PTH induced by a mild TBI (mTBI) in male or female mice. Methods Mice were lightly anesthetized and placed on a tissue paper stage prior to receiving a sham procedure or mTBI resulting from a closed-head weight drop injury. Behavioral responses to periorbital and hindpaw tactile (von Frey filaments) or thermal (hot plate) stimuli over the first 14 days post-mTBI were evaluated as measures of APTH. The PPTH phase was studied following the resolution of mTBI-induced APTH at days 14 and 28. PPTH was precipitated by exposure to bright lights (i.e., bright light stress, BLS). Olcegepant was delivered subcutaneously either repeatedly beginning 2 h after mTBI to produce a sustained block of CGRP-R signaling across the APTH phase, or as a single administration on days 14 or 28 post-mTBI to evaluate possible effects during the PPTH phase. Results mTBI, but not sham-procedure, produced periorbital and hindpaw tactile allodynia, as well as thermal hypersensitivity in mice of both sexes. APTH-related hypersensitivity was transient and resolved by day 14 post-injury. No sex differences were observed in the magnitude or duration of APTH-related pain behaviors. Sustained CGRP-R blockade was, however, significantly more effective in female than male mice in inhibiting pain behaviors in the APTH phase and in preventing the emergence of BLS-induced PPTH. CGRP-R blockade following the resolution of mTBI-induced APTH pain behaviors, on either day 14 or 28, minimally altered BLS-induced PPTH in either sex. Conclusions Sustained CGRP-R blockade starting soon after mTBI significantly inhibited APTH and prevented the expression of PPTH with greater analgesic effects in females compared to males. Delayed CGRP-R blockade beginning after resolution of APTH phase was minimally effective in preventing expression of PPTH in either sex. These data are consistent with previous observations that CGRP induces pain behaviors preferentially in females. Early and continuous CGRP blockade following mTBI may represent a viable treatment option for PTH treatment and the prevention of PTH persistence, especially in females.
Protocol and Study Population of a Prospective Study of Patients With Chronic Pancreatitis and Exocrine Pancreatic Insufficiency: Preliminary Findings From the PACT-CP Registry Show Reduced Health-related Quality of Life
Barkin, Jodie A. , Alkaade, Samer, Pannala, Rahul , Hernandez‐Barco, Yasmin G. , Twal, Janine, Pack, Jennifer, Nguyen, Dianne, Powell, Valerie J., Frommer, Cindy, D’Urzo, Carmine, Hernandez-Barco, Yasmin G , Whitcomb, David C.

Mayo Clinic

Pancreas | February 20, 2025 | Volume: 54 | Issue: 4 | Pages: e384-e386

10.1097/mpa.0000000000002460 | PMID 39977002 Get It

Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy
Cai, Cindy X. , Hribar, Michelle R. , Swaminathan, Swarup S. , Flowers, Alexis , Brown, Eric N. , Chen, John J. , Chen, Aiyin , Wang, Sophia Y. , Ehrlich, Joshua R. , Armbrust, Karen R. , Alshammari, Thamir , Swerdel, Joel N. , Suchard, Marc A. , Falconer, Thomas , DuVall, Scott L. , Viernes, Benjamin , O’Brien, William J. , Martin, Benjamin , Westlund, Erik , Mathioudakis, Nestoras , Fan, Ruochong, Stocking, Jacqueline C. , Takkouche, Sahar , Humes, Izabelle, McCoy, David , Adibuzzaman, Mohammad, Areaux, Raymond G. , Rojas‐Carabali, William , Brash, James T., Lee, David A. , Mawn, Louise A. , Agrawal, Rupesh, Morgan‐Cooper, Hannah, Desai, Priya , Ryan, Patrick , Barkmeier, Andrew, Chen, John J , Mathioudakis, Nestoras N , Stocking, Jacqueline C , Lee, Cecilia S , Baxter, Sally L. , Goetz, Kerry , Toy, Brian C. , Xu, Benjamin Yixing , Leng, Theodore , Barkmeier, Andrew J. , Boland, Michael V. , Dorr, David A , Boyce, Danielle M. , Schuemie, Martijn J. , Bu, Fan , Sena, Anthony G. , Hripcsak, George , Nishimura, Akihiko, Nagy, Paul G. , Matheny, Michael E. , Zhang, Linying , Martin, Benjamin, Fan, Ruochong, Wilcox, Adam B , Lai, Albert M. , Lee, Lok Hin , Xie, Yangyiran , Weiskopf, Nicole G. , Desai, Priya

Mayo Clinic

JAMA Ophthalmology | February 20, 2025 | Volume: 143 | Issue: 4 | Pages: 304

10.1001/jamaophthalmol.2024.6555 | PMID 39976940 Get It

Importance Semaglutide, a glucagonlike peptide-1 receptor agonist (GLP-1RA), has recently been implicated in cases of nonarteritic anterior ischemic optic neuropathy (NAION), raising safety concerns in the treatment of type 2 diabetes (T2D). Objective To investigate the potential association between semaglutide and NAION in the Observational Health Data Sciences and Informatics (OHDSI) network. Design, Setting, and Participants This was a retrospective study across 14 databases (6 administrative claims and 8 electronic health records). Included were adults with T2D taking semaglutide, other GLP-1RA (dulaglutide, exenatide), or non–GLP-1RA medications (empagliflozin, sitagliptin, glipizide) from December 1, 2017, to December 31, 2023. The incidence proportion and rate of NAION were calculated. Association between semaglutide and NAION was assessed using 2 approaches: an active-comparator cohort design comparing new users of semaglutide with those taking other GLP-1RAs and non–GLP-1RA drugs, and a self-controlled case-series (SCCS) analysis to compare individuals’ risks during exposure and nonexposure periods for each drug. The cohort design used propensity score–adjusted Cox proportional hazards models to estimate hazard ratios (HRs). The SCCS used conditional Poisson regression models to estimate incidence rate ratios (IRRs). Network-wide HR and IRR estimates were generated using a random-effects meta-analysis model. Exposures GLP-1RA and non–GLP-1RAs. Main Outcomes and Measures NAION under 2 alternative definitions based on diagnosis codes: one more inclusive and sensitive, the other more restrictive and specific. Results The study included 37.1 million individuals with T2D, including 810 390 new semaglutide users. Of the 43 620 new users of semaglutide in the Optum’s deidentified Clinformatics Data Mart Database, 24 473 (56%) were aged 50 to 69 years, and 26 699 (61%) were female. The incidence rate of NAION was 14.5 per 100 000 person-years among semaglutide users. The HR for NAION among new users of semaglutide was not different compared with that of the non–GLP-1RAs using the sensitive NAION definition—empagliflozin (HR, 1.44; 95% CI, 0.78-2.68; P = .12), sitagliptin (HR, 1.30; 95% CI, 0.56-3.01; P = .27), and glipizide (HR, 1.23; 95% CI, 0.66-2.28; P = .25). The risk was higher only compared with patients taking empagliflozin (HR, 2.27; 95% CI, 1.16-4.46; P = .02) using the specific definition. SCCS analysis of semaglutide exposure showed an increased risk of NAION (meta-analysis IRR, 1.32; 95% CI, 1.14-1.54; P < .001). Conclusions and Relevance Results of this study suggest a modest increase in the risk of NAION among individuals with T2D associated with semaglutide use, smaller than that previously reported, and warranting further investigation into the clinical implications of this association.
Characteristics of Patients With the Arrhythmogenic Mitral Valve Prolapse Syndrome and Sudden Cardiac Arrest and Sustained Ventricular Arrhythmias
Chakrabarti, Apurba , Giudicessi, John R. , Delling, Francesca N. , Dixit, Shalini , Lee, Yoo Jin , Muser, Daniele , Magnani, Silvia , Wijngaarden, Aniek L. van , Miller, Marc A. , Gandhi, Jonathan, Font, Jonaz , Martins, Raphaël P. , McCaffrey, James A. , Chapagain, Himal , Mathew, Don , Kancharla, Krishna , Syed, Faisal F. , Abid, Ahad, Cerbin, Lukasz , Garg, Lohit , Natale, Andrea , Enríquez, Andrés , Bogun, Frank , Ackerman, Michael J. , Liang, Jackson J. , Ezzeddine, Fatima , Delling, Francesca N , Lee, Yoo Jin , Muser, Daniele , Magnani, Silvia , van Wijngaarden, Aniek , Marsan, Nina Ajmone , Trivieri, Maria G , Font, Jonaz , Martins, Raphael , McCaffrey, James A , Santangeli, Pasquale , Marchlinski, Francis E , Chapagain, Himal , Mathew, Don , Kancharla, Krishna , Syed, Faisal F , Abid, Ahad , Tzou, Wendy , Della Rocca, Domenico G , Natale, Andrea , Mohanty, Sanghamitra , Sheldon, Seth H. , Kuo, Ling , Haugaa, Kristina , Aabel, Eivind W , Enriquez, Andres , Maeda, Shingo , Deshmukh, Amrish , Ackerman, Michael J , Liang, Jackson , Ezzeddine, Fatima M. , Marsan, Nina Ajmone , Santangeli, Pasquale , Marchlinski, Francis E. , Tzou, Wendy S. , Rocca, Domenico G. Della , Haugaa, Kristina H. , Aabel, Eivind W. , Deshmukh, Amrish , Ghannam, Michael

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | February 20, 2025 | Volume: 18 | Issue: 3 | Pages: No page available

10.1161/circep.124.013099 | PMID 39973752 Get It

BACKGROUND: Patients with arrhythmogenic mitral valve prolapse syndrome are at increased risk for life-threatening ventricular arrhythmias, but studies have been limited by small sample sizes. We sought to assemble an international arrhythmogenic mitral valve prolapse syndrome registry to delineate the clinical, imaging, and treatment characteristics of patients with arrhythmogenic mitral valve prolapse syndrome who survived sudden cardiac arrest (SCA) or had sustained ventricular tachycardia (VT) or ventricular fibrillation. METHODS: In this descriptive registry, we characterized patients with arrhythmogenic mitral valve prolapse syndrome who survived SCA, sustained VT, or ventricular fibrillation. Deidentified data were abstracted locally and combined centrally. RESULTS: We included 148 patients who had SCA or VT/ventricular fibrillation. Patients had a mean age of 43.7±15.4 years; 68% were women, 73% had bileaflet prolapse, 65% had mitral annular disjunction, 67% had nonsustained VT, and 59% had inferolateral T-wave inversions. Syncope (n=54, 48%) and anterolateral T-wave inversion (n=26, 22%) were relatively common. Catheter ablation was performed in 50 (35%) patients for premature ventricular complexes and in 18 (17.7%) patients for VT. Sites of origin for arrhythmias were commonly in the papillary muscles, fascicles, mitral annulus, and inferior/inferolateral left ventricle. CONCLUSIONS: In this international descriptive registry of patients with arrhythmogenic mitral valve prolapse syndrome and SCA, patients were young, women, and had bileaflet mitral valve prolapse, mitral annular disjunction, inferolateral T-wave inversions, and nonsustained VT. A history of syncope and anterolateral T-wave inversions was relatively common in patients who survived SCA or sustained VT/ventricular fibrillation.
Multiple Neuropathologies Underly Hippocampal Subfield Atrophy in a Case With a Slowly Progressive Amnestic Syndrome: Challenging the Notion of Pure LATE ‐ NC
Gatto, Rodolfo G. , Pham, Nha Trang Thu, Petersen, Ronald C. , Whitwell, Jennifer L. , Josephs, Keith A. , Youseff, Hossam , Josephs, Keith A , Whitwell, Jennifer L , Youssef, Hossam , Jones, David T. , Machulda, Mary M.

Mayo Clinic

Neuropathology | February 20, 2025 | Volume: 45 | Issue: 4 | Pages: No page available

10.1111/neup.70000 | PMID 39973236 Get It

ABSTRACT Alzheimer's disease (AD) is the leading cause of dementia in the elderly, marked by abnormal protein buildup (beta‐amyloid and tau) resulting in neuronal loss, especially in the medial temporal lobe and other limbic regions. The presence of transactive response DNA binding protein 43 (TDP‐43) immunoreactive inclusions in medial temporal lobe regions has also been associated with neuroimaging changes in limbic regions. It has been proposed that hypometabolism in limbic regions on [ 18 F] fluorodeoxyglucose positron emission tomography (FDG‐PET) in a patient with a slowly evolving amnestic syndrome may be a signature of the presence of TDP‐43. In this context, we observed an 86‐year‐old Caucasian female with dementia characterized by a slowly evolving amnestic syndrome, along with focal medial temporal atrophy evident on MRI and hypometabolism in limbic regions on FDG‐PET. The patient subsequently died and underwent an autopsy. We performed detailed neuroimaging and digital neuropathological analyses of the hippocampal subfields to better understand the relationship between clinico‐imaging findings and histopathology. In addition to TDP‐43, we identified three other pathological processes in the medial temporal lobe: sequestosome‐1/p62, argyrophilic grain disease (AGD), and primary age‐related tauopathy (PART). Hippocampal subfield volumes and rates of atrophy were no different from those of matched healthy controls, except for the atrophy rate in cornu ammonis 1 (CA1). Digital histopathology revealed the relative highest burden of pathology for p62, followed by TDP‐43, AGD, and PART in CA1. Multiple pathological processes appear to have contributed to the hippocampal atrophy and hypometabolism in our patient with a slowly progressive amnestic syndrome.
Lipodystrophy Severity Score to Assess Disease Burden in Lipodystrophy
Brown, Rebecca J. , Akıncı, Barış , Yosef, Matheos , Phillips, Helen , Khalatbari, Shokoufeh , Santini, Ferruccio , Brush, Maiah, Meral, Rasimcan , Prodam, Flavia , Schnurbein, Julia von , Sorice, Gian Pio , Güler, Merve Çelik , Patni, Nivedita , Tanrıkulu, Seher , Ozgen, Basak S, Foss‐Freitas, Maria Cristina , Özışık, Seçil , Segrestin, Bérénice , Özcan, Büşra, Adıyaman, Süleyman Cem , Musolino, Gianluca , Sekizkardes, Hilal , Musso, Carla , Simha, Vinaya , Stears, Anna, Gambineri, Alessandra , Semple, Robert K. , Prodam, Flavia , von Schnurbein, Julia , Sekizkardes, Hilal , Lebenthal, Yael , Simha, Vinaya , Wabitsch, Martin , Oral, Elif A , Brown, Rebecca J. , Sorkina, Ekaterina , Vigouroux, Corinne , Ceccarini, Giovanni , Zeybel, Müjdat , Al-Yaarubi, Saif , Ozgen, Basak S, Özen, Samim , Şimşir, İlgın Yıldırım , Scherer, Thomas , Lima, Josivan Gomes , Araújo‐Vilar, David , Hegele, Robert Alexander , Oral, Elif A

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | February 19, 2025 | Volume: 110 | Issue: 11 | Pages: 3243-3255

10.1210/clinem/dgaf103 | PMID 39970125 Get It

Abstract Context Lipodystrophy syndromes are rare disorders characterized by deficient adipose tissue, leading to insulin resistance, dyslipidemia, and organ system abnormalities. Objective Our goal was to develop a lipodystrophy severity score (LDS) to holistically capture the diverse manifestations of lipodystrophy into a numerical score to aid in prediction of clinical outcomes and/or treatment impact. Design An 8-domain LDS was developed by 8 disease experts in consultation with patient organizations. The LDS was rated for feasibility and content validity by 28 additional clinicians and 9 patient representatives. LDS was compared to the Clinical Global Impression (CGI) of severity for 20 putative patient profiles, each at 2 different time points, and by comparing change in LDS to global impression of change. For external validation, LDS was calculated in 2 cohorts of patients with lipodystrophy treated with metreleptin. Results LDS domains include Diabetes/Insulin Resistance, Microvascular Complications of Diabetes, Lipids, Cardiovascular, Liver, Kidney, Reproductive, and Other. Each domain is assessed by 1 or more questions assessing both lifetime and recent complications of lipodystrophy. The LDS had high content validity and feasibility and high reliability by intraclass correlation coefficients (>0.95). Global and domain-specific LDS were strongly correlated with CGI, as were changes in scores across visits (R = 0.79-0.99, P < .001 for all). In generalized lipodystrophy, metreleptin significantly reduced LDS (from 46 to 26 at 12 months, P < .001). The reductions were smaller in partial lipodystrophy (from 65 to 61 at 12 months, P = .04). Conclusion The LDS can reflect the severity of diverse manifestations of lipodystrophy and monitor changes following interventions.
Dissociable spatial topography of cortical atrophy in early‐onset and late‐onset Alzheimer's disease: A head‐to‐head comparison of the LEADS and ADNI cohorts
Katsumi, Yuta , Touroutoglou, Alexandra , Brickhouse, Michael , Eloyan, Ani , Eckbo, Ryan, Zaitsev, Alexander, Joie, Renaud La , Thangarajah, Maryanne, Taurone, Alexander, Jack, Clifford R. , Dage, Jeffrey L. , Hammers, Dustin B. , Newell, Kathy L. , Polsinelli, Angelina J. , Aisen, Paul, Reman, Rema, Kramer, Joel H. , Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Grant, Ian , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Stephen , Sha, Sharon, Turner, Raymond Scott , Wingo, Thomas S. , Carrillo, María C. , Rabinovici, Gil D. , Apostolova, Liana G. , Jack, Clifford R , Day, Gregory S , La Joie, Renaud , Rabinovici, Gil D , Wingo, Thomas S , Dage, Jeffrey L , Lagarde, Julien , Schonhaut, Daniel R. , Vemuri, Prashanthi , Nudelman, Kelly , Foroud, Tatiana , Hammers, Dustin B , Ghetti, Bernardino , Murray, Melissa E. , Beckett, Laurel , Atri, Alireza , Duara, Ranjan , Honig, Lawrence S. , Johnson, Erik C. B. , Jones, David T. , Masdeu, Joseph C , Musiek, Erik , Sha, Sharon J. , Wolk, David A. , Womack, Kyle , Dickerson, Bradford Clark

Mayo Clinic

Alzheimer's & Dementia | February 19, 2025 | Volume: 21 | Issue: 2 | Pages: No page available

10.1002/alz.14489 | PMID 39968692 Get It

Abstract INTRODUCTION Early‐onset and late‐onset Alzheimer's disease (EOAD and LOAD, respectively) have distinct clinical manifestations, with prior work based on small samples suggesting unique patterns of neurodegeneration. The current study performed a head‐to‐head comparison of cortical atrophy in EOAD and LOAD, using two large and well‐characterized cohorts (LEADS and ADNI). METHODS We analyzed brain structural magnetic resonance imaging (MRI) data acquired from 377 sporadic EOAD patients and 317 sporadicLOAD patients who were amyloid positive and had mild cognitive impairment (MCI) or mild dementia (i.e., early‐stage AD), along with cognitively unimpaired participants. RESULTS After controlling for the level of cognitive impairment, we found a double dissociation between AD clinical phenotype and localization/magnitude of atrophy, characterized by predominant neocortical involvement in EOAD and more focal anterior medial temporal involvement in LOAD. DISCUSSION Our findings point to the clinical utility of MRI‐based biomarkers of atrophy in differentiating between EOAD and LOAD, which may be useful for diagnosis, prognostication, and treatment. Highlights Early‐onset Alzheimer's disease (EOAD) and late‐onset AD (LOAD) patients showed distinct and overlapping cortical atrophy patterns. EOAD patients showed prominent atrophy in widespread neocortical regions. LOAD patients showed prominent atrophy in the anterior medial temporal lobe. Regional atrophy was correlated with the severity of global cognitive impairment. Results were comparable when the sample was stratified for mild cognitive impairment (MCI) and dementia.
Aberrant Internal Carotid Artery With Spontaneous Pseudoaneurysm of the Middle Ear
Ali, Hawa M. , Valencia, David M., Lane, John I. , Brinjikji, Waleed , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | February 18, 2025 | Volume: 46 | Issue: 4 | Pages: e147-e148

10.1097/mao.0000000000004434 | PMID 39965224 Get It

Do Surgeons Treat Their Patients’ Upper Extremity Nerve Palsies as They Would Treat Their Own?
Krijnen, Nienke A. , Arellano, José Antonio , Wu, Kitty Y. , Group, Science of Variation, Ring, David , Teunis, Teun , Group, Science of Variation

Mayo Clinic

Plastic & Reconstructive Surgery | February 18, 2025 | Volume: 156 | Issue: 4 | Pages: 624-632

10.1097/prs.0000000000012044 | PMID 39965174 Get It

Background: Early surgical intervention in nerve palsies with a high probability of nerve integrity and natural recovery risks unnecessary surgery. Understanding the variables influencing surgeons to offer surgery might provide insight into variations in surgeon beliefs and guide treatment recommendations. Methods: Sixty-nine surgeons of the Science of Variation Group participated in a survey consisting of 6 traumatic and 3 nontraumatic nerve palsy scenarios. Participants were asked what their preferred treatment was and how likely they were to offer surgery on a scale from 0 to 10. Participants were randomized to choose for themselves (n = 31) or for a patient of their age and sex (n = 38). Results: There was no difference in the overall likelihood of offering surgery or in the types of treatment offered to patients compared with oneself. Surgery was least recommended for idiopathic palsies and most for ulnar (β = 0.91; 95% CI, 0.10 to 1.7; P = 0.027) or radial (β = 0.92; 95% CI, 0.12 to 1.7; P = 0.025) nerve palsy following closed distal radius or humerus fractures. Longer symptom duration increased the likelihood of offering surgery. Conclusions: Surgeons were moderately likely to recommend surgery for nerve palsies, with no variation in opinions regardless of whether they were deciding for themselves or for patients. For specific nerve palsies with a documented benign natural history, this likely represents overtreatment. Future studies can assess whether balancing awareness of a benign natural history with the pressure to act and the sense that recovery is “taking too long” might limit the offer of unnecessary surgery.